Turning Point Brands, Inc.

Turning Point Brands, Inc. (TPB) Market Cap

Turning Point Brands, Inc. has a market capitalization of $1.35B.

Financials based on reported quarter end 2025-12-31

Price: $70.43

-14.11 (-16.69%)

Market Cap: 1.35B

NYSE · time unavailable

CEO: Graham A. Purdy

Sector: Consumer Defensive

Industry: Tobacco

IPO Date: 2016-05-11

Website: https://www.turningpointbrands.com/home/default.aspx

Turning Point Brands, Inc. (TPB) - Company Information

Market Cap: 1.35B · Sector: Consumer Defensive

Turning Point Brands, Inc., together with its subsidiaries, manufactures, markets, and distributes branded consumer products. The company operates through three segments: Zig-Zag Products, Stoker's Products, and NewGen Products. The Zig-Zag Products segment markets and distributes rolling papers, tubes, finished cigars, make-your-own cigar wraps, and related products under the Zig-Zag brand. The Stoker's Products segment manufactures and markets moist snuff tobacco and loose-leaf chewing tobacco products under the Stoker's, Beech-Nut, Durango, Trophy, and Wind River brands. The NewGen Products segment markets and distributes cannabidiol isolate, liquid vapor products, and other products without tobacco and/or nicotine to individual consumers through VaporFi B2C online platform, as well as non-traditional retail through VaporBeast. It sells its products to wholesale distributors and retail merchants in the independent and chain convenience stores, tobacco outlets, food stores, mass merchandising, and drug stores. The company was formerly known as North Atlantic Holding Company, Inc. and changed its name to Turning Point Brands, Inc. in November 2015. Turning Point Brands, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Analyst Sentiment

81%
Strong Buy

Based on 12 ratings

Analyst 1Y Forecast: $117.50

Average target (based on 2 sources)

Consensus Price Target

Low

$110

Median

$120

High

$130

Average

$120

Potential Upside: 70.4%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 TURNING POINT BRANDS INC (TPB) — Investment Overview

🧩 Business Model Overview

Turning Point Brands Inc (TPB) is a diversified consumer products company operating in the Other Tobacco Products (OTP), Vapor, and Alternative Products sectors. The company manufactures, markets, and distributes branded consumer products with an emphasis on the growing segments of the nicotine, alternative smoking, and broader lifestyle categories. Its portfolio features iconic heritage brands as well as innovative offerings that cater to evolving consumer preferences. TPB utilizes a blend of direct-store distribution, third-party distribution, and e-commerce platforms to reach both wholesale and retail customers. The company’s strategic focus on niche, high-margin markets differentiates it from larger tobacco conglomerates, fostering agility and responsiveness within highly regulated industries.

💰 Revenue Streams & Monetisation Model

Turning Point Brands generates income from three primary operating segments: 1. **Zig-Zag & Other Smoking Products**: This category comprises rolling papers, cigar wraps, tubes, and related accessories under legacy brands such as Zig-Zag. Revenue is derived from domestic and international sales to both wholesalers and retailers, including specialty tobacco shops, convenience stores, and online platforms. 2. **Stoker’s & Smokeless Products**: The Stoker’s sub-brand encompasses moist snuff and loose leaf chewing tobacco, delivering steady cash flows from traditional tobacco consumers. This product line maintains resilient demand due to brand loyalty and established distribution in rural and heartland markets. 3. **NewGen Products & E-vapor**: TPB leverages strategic investments in vaping and alternative nicotine delivery systems, including third-party brands on its VaporBeast and International Vapor Group platforms. This segment also includes cannabidiol (CBD) and modern oral nicotine products, aiming to capture growth among consumer segments seeking reduced-risk alternatives. Overall, TPB’s monetisation is supported by diversified channels such as direct-store delivery networks, third-party distribution agreements, and wholly owned e-commerce marketplaces. The company’s efficiency in procurement, brand management, and regulatory compliance further enhances its monetisation capabilities.

🧠 Competitive Advantages & Market Positioning

Turning Point Brands distinguishes itself among tobacco and alternative product companies through several durable competitive advantages: - **Iconic, Trusted Brands**: Zig-Zag is a globally recognized name in rolling papers, while Stoker’s commands loyalty among traditional smokeless tobacco users. These brands offer pricing power and shelf-stability in a commoditized marketplace. - **Regulatory Acumen**: The company’s deep experience navigating complex and shifting regulatory landscapes in the U.S. and abroad serves as a barrier to entry for less experienced peers, particularly in emerging segments such as vapor and CBD. - **Distribution Scale and Reach**: TPB operates a robust distribution network that reaches tens of thousands of retail outlets and specialty shops, providing a defensible channel advantage and consistent shelf presence. - **Agility and Innovation**: Unlike industry giants, TPB boasts an entrepreneurial culture that enables the rapid introduction of new products—including alternative nicotine and CBD offerings—while maintaining compliance. - **Niche Market Focus**: By targeting segments underpenetrated by multinational tobacco companies, TPB attracts less competition and nurtures high-margin, loyal customer bases.

🚀 Multi-Year Growth Drivers

Multiple secular and company-specific drivers underpin TPB’s long-term growth prospects: - **Evolving Consumer Preferences**: Shifts away from combustible cigarettes towards vapor, modern oral nicotine, and CBD represent expansion opportunities, with TPB positioned through early investments and third-party partnerships. - **Product Innovation**: Ongoing development and rollout of new products—such as hemp-derived CBD, alternative smokeless products, and advanced vapor devices—foster revenue diversification and enhance margin profiles. - **Geographic Expansion**: International market entry, particularly in rolling papers and alternative smoking products, offers runway for incremental volume growth as global regulations liberalize. - **Mergers and Acquisitions**: The company maintains an opportunistic approach to bolt-on acquisitions in adjacent categories, leveraging its scale and expertise to drive further growth. - **Regulatory Tailwinds**: As regulators scrutinize combustible-only offerings, companies with robust compliance frameworks and broader product portfolios, like TPB, stand to gain share as competitors exit or retrench.

⚠ Risk Factors to Monitor

While TPB exhibits numerous strengths, investors should remain cognizant of salient risks: - **Regulatory Uncertainty**: Frequent changes to federal, state, and local tobacco, vapor, and CBD regulations can impair product lines, distribution, or require expensive compliance changes. - **Legal and Litigation Risks**: Potential exposure to class action lawsuits or penalties related to alleged marketing practices, health claims, or product content remains material. - **Consumer Health Trends**: Increasing public health campaigns and social stigma could dampen market size for certain tobacco and nicotine categories. - **Supply Chain Disruptions**: Reliance on a narrow set of suppliers, especially for paper and specialized inputs, may expose the company to cost volatility or shortages. - **Product Substitution**: Rapid consumer adoption of yet-unknown alternatives or technology shifts could erode demand for core product lines. - **Competitive Response**: Entry or aggressive pivot by multinational players into TPB’s core niches could intensify price competition and pressure margins.

📊 Valuation & Market View

Turning Point Brands is frequently valued using a mix of earnings-based multiples, relative to both legacy tobacco peers and high-growth alternative product firms. The company often trades at a moderate premium to traditional tobacco due to its differentiated growth profile, diversified portfolio, and exposure to emerging categories. Valuation frameworks take into account steady free cash flow from smokeless and rolling paper segments, higher-multiple potential from e-vapor and CBD platforms, and optionality from new product launches. TPB’s asset-light model, moderate leverage, and healthy dividend payments enhance its appeal to both value and growth-oriented portfolios. Market participants typically assess TPB as a blend between “cash cow” legacy tobacco and “call option” on the future of alternative nicotine.

🔍 Investment Takeaway

Turning Point Brands represents a unique investment within the tobacco and alternative nicotine sectors. Its portfolio of iconic brands, diversified revenue base, and distribution reach create a defensible foundation, while exposure to secular growth in vapor, modern oral, and CBD provides structural upside. The company’s agility in navigating regulatory challenges and in executing product innovation positions it favorably, albeit with risks inherent to regulatory and consumer shifts. For investors seeking a balanced play on both the stability of traditional tobacco economics and the dynamism of emerging nicotine categories, TPB offers a compelling, differentiated value proposition. Comprehensive due diligence around regulatory risk, innovation pipeline, and competitive dynamics remains essential for prudent capital allocation.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"TPB reported a revenue of $121.01M and net income of $8.21M for the year ending December 31, 2025. The company holds total assets of $763.75M against total liabilities of $391.77M, resulting in total equity of $371.98M. Significant cash flow metrics include operating cash flow of $27.64M and a free cash flow of approximately $24.30M, indicating solid operational efficiency. Although dividends have been paid amounting to $1.43M, shareholder returns are more prominently reflected in a substantial 47.07% price increase over the past year, suggesting positive market sentiment. Despite a decline of 21.24% year-to-date and a 15.66% drop over the last six months, the share price currently stands at $86.83, well below the consensus target of $120. TPB's balance sheet demonstrates modest leverage with a net debt of $86.21M. Given these factors, TPB showcases strong growth potential, solid profitability, and effective cash flow management, although recent downward trends may raise caution with shorter-term investors."

Revenue Growth

Good

Strong revenue growth with $121.01M, showing healthy expansion.

Profitability

Positive

Positive net income of $8.21M and EPS of $0.43 highlight profitability.

Cash Flow Quality

Good

Operating cash flow of $27.64M and free cash flow of $24.30M indicate strong cash generation.

Leverage & Balance Sheet

Positive

Manageable leverage with net debt of $86.21M in relation to equity.

Shareholder Returns

Strong

Impressive 47.07% price increase over the past year reflects strong shareholder returns.

Analyst Sentiment & Valuation

Neutral

Current share price below target suggests potential undervaluation but recent negative trends raise concern.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management is clearly bullish on Modern Oral momentum: Q4 revenue +29% to $121M with Modern Oral net revenue of $41.3M and +266% YoY net white pouch sales. Guidance is also pointed—2026 Modern Oral net revenue of $180M–$190M and Q1 2026 consolidated adjusted EBITDA of $24M–$27M—while ALP’s bricks-and-mortar rollout is already beginning (expected to accelerate in Q2). However, the Q&A reveals real friction beneath the growth narrative. The biggest concrete headwind was tariffs: an elevated Q4 tariff rate pressured Stoker’s gross margins due to white pouch exposure (not something merely smoothed out by adjusted EBITDA). Additionally, management admitted EBITDA beyond Q1 is hard to forecast because of lumpy, front-loaded sales/marketing investments and the required upfront ALP launch spend. Analyst pressure focused on production ramp, ALP store growth timing, and margin drivers—areas where uncertainty persists even as management highlights “green shoots” later in the year.

AI IconGrowth Catalysts

  • Modern Oral nicotine pouch net revenue of $41.3M; net white pouch sales +266% YoY
  • ALP running ahead of schedule vs prior expectation of D2C-only in 2025; initial bricks-and-mortar retailer tests started
  • Freeze distribution expansion to large regional and national c-store chains
  • FRE and ALP prioritized within route-to-market; increased sales/marketing and sales force ramp

Business Development

  • ALP appearing in select retailer tests; management expects significant bricks-and-mortar expansion during Q2
  • FRE partnership: 'Probo Writing Association partnership' referenced as a key brand distribution/equity driver
  • Chain wins focus for distribution execution in 2026 (store count growth expected to be somewhat lumpy)

AI IconFinancial Highlights

  • Revenue +29% YoY to $121M; Modern Oral contributes $41.3M net revenue
  • Adjusted EBITDA +14% YoY to $30M (24.8% EBITDA margin)
  • Initiating 2026 Modern Oral guidance: gross sales $220M–$240M; net revenue $180M–$190M
  • Q1 2026 consolidated adjusted EBITDA guidance: $24M–$27M (management cites white pouch sales/marketing investments as drivers making longer-range EBITDA projection difficult)
  • Q4 consolidated gross margin 55.9% (flat YoY); Zig-Zag gross margin 54.6% (+40 bps vs last year)
  • Stoker's segment net sales +70% YoY to $81M; segment now 67% of consolidated net sales
  • Zig-Zag revenue down 13% YoY to $40M; management frames decline as anticipated opportunity costs from laser focus on Modern Oral
  • Effective income tax rate guidance: 23%–26% on go-forward basis
  • Stroker's Q4 gross margin pressure linked to 'elevated tariff rate' in the quarter (tariff impact on margins; add-back noted only in adjusted EBITDA, not gross margin)

AI IconCapital Funding

  • Cash on hand: $222.8M at quarter end
  • Free cash flow: $19.2M in Q4
  • CapEx: $3.3M in Q4
  • Budgeted CapEx for 2026: $4M–$5M (exclusive of Modern Oral-related projects)
  • Additional Modern Oral PMTA supplement spend: $3M–$5M for full year 2026

AI IconStrategy & Ops

  • Domestic production: qualify first production lines at new 'ruble' factory over the next several months; lines expected to be qualified within the next couple of months (Q&A)
  • CapEx spent in 2025 on infrastructure for production (HVAC, electrical, plumbing); lines becoming more efficient 'week by week'
  • U.S. manufacturing approach: continue using an 'Indian partner' to avoid supply constraints; U.S. production will supplement growth
  • Margin mitigation lever: 'very much focused on freight' (inbound freight optimization to improve margin profile; green shoots toward end of year)
  • Sales force: ahead of schedule toward doubling sales force size

AI IconMarket Outlook

  • ALP retail expansion: management expects significant bricks-and-mortar distribution expansion during Q2
  • Store count ramp expectation for ALP: 'similar to the early days of the FRE launch' (Q&A)
  • Store opportunity framing (FRE): continued store growth expected in 2026, but may be lumpy vs timing of chain openings; emphasis on winning shelf space within stores rather than only adding stores
  • Long-term: target double-digit market share in the nicotine pouch category; management suggests 5–6 widely distributed brands by end of decade

AI IconRisks & Headwinds

  • Tariffs: elevated tariff rate in Q4 pressured Stoker's margins because of white pouch; tariff impact is in gross margins (not offset in adjusted EBITDA add-back)
  • Modern Oral investment front-loading creates uncertainty beyond Q1: management cites sales/marketing initiatives making it difficult to project EBITDA beyond Q1 guidance
  • Zig-Zag decline: revenue down 13% YoY (down 9% sequentially) driven by anticipated opportunity costs from focusing resources on Modern Oral
  • Margin improvement timing risk: inventory build/out of U.S. and through P&L expected to take time; margin enhancements expected later ('towards the end of the year')

Sentiment: MIXED

Note: This summary was synthesized by AI from the TPB Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (TPB)

© 2026 Stock Market Info — Turning Point Brands, Inc. (TPB) Financial Profile